Table 4.
Overall Survival of Patients With Endometrial Cancer.a
| Characteristic | No. | 5-year (%) | Univariate |
Multivariate |
||
|---|---|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | |||
| Age | <.001 | .61 | ||||
| <60 | 537 | 89.8% | 1 | 1 | ||
| ≥60 | 177 | 74.8% | 2.88 (1.75-4.74) | 1.20 (0.60-2.41) | ||
| Ethnicity | .015 | .26 | ||||
| Non-Hispanic | 234 | 80.1% | 1 | 1 | ||
| Hispanic | 480 | 89.4% | 0.55 (0.34-0.90) | 0.70 (0.38-1.30) | ||
| BMI (kg/m2) | .16 | .75 | ||||
| <30 | 218 | 84.0% | 1 | 1 | ||
| ≥30 | 490 | 88.1% | 0.70 (0.43-1.15) | 1.11 (0.59-2.07) | ||
| Hypertension | .84 | .15 | ||||
| No | 320 | 86.1% | 1 | 1 | ||
| Yes | 394 | 87.7% | 0.95 (0.59-1.54) | 1.69 (0.82-3.46) | ||
| β-Blocker use | .34 | .40 | ||||
| No | 585 | 86.0% | 1 | 1 | ||
| Yes | 129 | 89.3% | 0.72 (0.37-1.41) | 0.72 (0.33-1.57) | ||
| Diabetes Mellitus | .29 | .25 | ||||
| No | 484 | 86.0% | 1 | 1 | ||
| Yes | 230 | 87.1% | 0.75 (0.44-1.28) | 1.73 (0.68-4.38) | ||
| Metformin use | .12 | .86 | ||||
| No | 546 | 86.2% | 1 | 1 | ||
| Yes | 168 | 88.1% | 0.61 (0.33-1.14) | 0.91 (0.34-2.46) | ||
| Hypercholesterolemia | .44 | .99 | ||||
| No | 537 | 86.4% | 1 | 1 | ||
| Yes | 176 | 87.1% | 0.80 (0.45-1.42) | 1.01 (0.45-2.25) | ||
| Statin use | .03 | .88 | ||||
| No | 576 | 84.9% | 1 | 1 | ||
| Yes | 138 | 92.8% | 0.45 (0.22-0.94) | 1.08 (0.40-2.93) | ||
| NAFLD | <.001 | .038 | ||||
| No | 533 | 82.2% | 1 | 1 | ||
| Yes | 181 | 95.8% | 0.25 (0.12-0.51) | 0.35 (0.13-0.94) | ||
| CA-125 (IU/L) | <.001 | .027 | ||||
| <35 | 457 | 93.9% | 1 | 1 | ||
| ≥35 | 177 | 69.0% | 6.40 (3.68-11.1) | 2.12 (1.09-4.13) | ||
| Platelet count (× 109/L) | <.001 | .72 | ||||
| <400 | 590 | 90.8% | 1 | 1 | ||
| ≥400 | 79 | 67.2% | 3.47 (2.03-5.96) | 0.89 (0.48-1.65) | ||
| Histology subtype | <.001 | .038 | ||||
| Endometrioid | 591 | 92.4% | 1 | 1 | ||
| Nonendometrioid | 123 | 62.5% | 6.52 (4.02-10.6) | 1.95 (1.04-3.68) | ||
| Grade | <.001 | .064 | ||||
| 1-2 | 550 | 93.6% | 1 | 1 | ||
| 3 | 164 | 64.8% | 6.43 (3.92-10.6) | 1.92 (0.96-3.83) | ||
| Stage | <.001 | <.001 | ||||
| I-II | 554 | 94.5% | 1 | 1 | ||
| III-IV | 160 | 65.5% | 10.9 (6.15-19.4) | 5.42 (2.38-12.3) | ||
| VTE | <.001 | <.001 | ||||
| No | 657 | 92.1% | 1 | 1 | ||
| Yes | 57 | 34.8% | 13.3 (8.05-22.1) | 4.45 (2.16-9.17) | ||
Abbreviations: BMI, body mass index; CA, cancer antigen; CI, confidence interval; HR, hazard ratio; NAFLD, nonalcoholic fatty liver disease; VTE, venous thromboembolism; 5-yr (%), 5-year survival proportion.
a
Multivariate analysis with Cox proportional hazards regression test for P values. Significant P values are emboldened.